Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series-Reference-Cited by-同舟云学术

Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series

Published:2023-11 Issue:7 Volume:24 Page:666-671
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Fricke Jeremy,Wang Joshua,Gallego Natalie,Mambetsariev Isa,Kim Pauline,Babikian Razmig,Chen Bihong T.,Afkhami Michelle,Subbiah Vivek,Salgia Ravi^ORCID

Funder

National Cancer Institute

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. Cancer statistics, 2023;Siegel;CA Cancer J Clin,2023

2. RET rearrangements in non-small cell lung cancer: evolving treatment landscape and future challenges;Servetto;Biochim Biophys Acta Rev Cancer,2022

3. The new kid on the block: RET in lung cancer;Gainor;Cancer Discov,2013

4. Evaluation of somatic mutations in solid metastatic pan-cancer patients;Roosan;Cancers (Basel),2021

5. RET fusion gene: translation to personalized lung cancer therapy;Kohno;Cancer Sci,2013

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs”;Cancers;2024-08-19

2. RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future;Drugs;2024-07-13

3. Peritoneal effusion: an uncommon adverse effect of selective RET inhibitors;Annals of Oncology;2024-05

4. Pralsetinib/selpercatinib;Reactions Weekly;2024-04-27

5. Spontaneous Bilateral Chylothorax Development During Alectinib Therapy for ALK-Rearranged NSCLC—A Case Report;JTO Clinical and Research Reports;2023-12